Regulatory Approval
Glenmark Receives U.S. FDA Approval to Expand RYALTRIS® Use for Children Aged 6 to Less Than 12 Years
NSE
glenmark
BSE
532296
- Glenmark Pharmaceuticals Limited announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of RYALTRIS® Nasal Spray for treating Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years.
- The approval broadens the product’s addressable patient population in the U.S. and strengthens Glenmark’s respiratory specialty portfolio following its transition to direct commercialization of RYALTRIS® in the country.
PRICE-SENSITIVE TRIGGER
Event: The U.S. FDA approved the expanded indication for RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray for pediatric patients aged 6 to less than 12 years suffering from Seasonal Allergic Rhinitis.
Type: Regulatory Approval
Impact: Positive
Immediate Effect: The approval enables Glenmark to market RYALTRIS® to a younger pediatric population in the United States, expanding the product’s commercial opportunity while reinforcing its innovation-led respiratory portfolio.
Metrics:
Key Metrics:
- Product: RYALTRIS® Nasal Spray
- Regulatory Authority: U.S. Food and Drug Administration (FDA)
- Approved Patient Age: 6 years to less than 12 years
- Previous Approved Age Group: Adults and pediatric patients aged 12 years and above
- Current Approved Population: Adults and pediatric patients aged 6 years and older
- Phase 3 Study Size: 446 pediatric patients
- Treatment Duration in Clinical Trial: 14 days
- Global Markets Approved: 56 countries
- Additional Markets Launched in FY26: 11
Highlight:
- The FDA approval expands RYALTRIS® into a younger pediatric segment, increasing the product’s addressable market while strengthening Glenmark’s U.S. respiratory franchise.
What Happened ?
The U.S. FDA approved the label expansion for RYALTRIS® Nasal Spray, allowing its use in children aged 6 to less than 12 years for the treatment of Seasonal Allergic Rhinitis. The approval was supported by positive Phase 3 clinical data demonstrating improved nasal symptom relief compared with placebo and a favorable safety profile.
The regulatory milestone comes after Glenmark assumed direct responsibility for commercialization and distribution of RYALTRIS® in the United States from 1 April 2026, enabling greater control over brand strategy, market access and customer engagement.
key details
Regulatory & Business Updates:
- The U.S. FDA approved the expanded indication for RYALTRIS® Nasal Spray for pediatric patients aged 6 to less than 12 years with Seasonal Allergic Rhinitis.
- The approval was supported by a Phase 3 randomized, double-blind, placebo-controlled clinical study involving 446 children aged 6–11 years.
- Clinical data demonstrated that RYALTRIS® significantly improved nasal symptoms compared with placebo and was well tolerated during the 14-day treatment period.
- RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and above.
- Glenmark Pharmaceuticals Inc., USA assumed end-to-end commercialization and distribution of RYALTRIS® from 1 April 2026, covering brand strategy, market access, distribution and customer engagement.
- RYALTRIS® combines olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid) in a single fixed-dose nasal spray.
- The product has regulatory approvals across major global markets including the European Union, United Kingdom, Australia, South Korea, Russia and China.
- During FY26, RYALTRIS® was launched in 11 additional markets, expanding its presence to 56 countries.
Note:
- The announcement relates to a regulatory approval and does not disclose expected revenue contribution, sales guidance, market share targets or financial impact arising from the expanded indication.
Risk Analysis
Summary:
- The FDA approval strengthens Glenmark’s specialty respiratory portfolio and expands its commercial opportunity. However, long-term financial benefits will depend on physician adoption, prescription growth, reimbursement, and successful execution of Glenmark’s direct commercialization strategy in the U.S.
Key Risks:
- Commercial success depends on physician prescribing and patient adoption.
- Revenue growth will depend on market penetration within the expanded pediatric population.
- Competition from alternative allergic rhinitis therapies may influence market share.
- Continued regulatory compliance and post-marketing safety monitoring remain essential.
- Financial benefits will materialize progressively through commercial execution rather than immediately after approval.
Worst Case:
- If physician adoption remains limited or commercial execution falls short, the expanded indication may have only a modest impact on RYALTRIS® sales despite the regulatory approval.
Risk Level: Low
Company Commentary
- Glenmark stated that the approval represents an important step in expanding patient access to RYALTRIS® in the United States.
- The company believes the expanded indication strengthens RYALTRIS® as a key innovative brand within its growing U.S. respiratory portfolio.
- Management highlighted that direct commercialization provides greater ownership of the brand and enables closer engagement with healthcare professionals and patients.
- Glenmark intends to leverage its commercialization platform to expand access, strengthen the RYALTRIS® franchise and reinforce its innovation-led presence in the U.S. specialty pharmaceutical market.
Official Exchange Filing: Glenmark Pharmaceuticals Limited
